Growth momentum Sanguine Biosciences is expanding its clinical sample portfolio with new Synovial Fluid and Skin Punch Biopsy collections, signaling opportunities to cross-sell additional biospecimen types, annotated data services, and study support to pharma partners pursuing musculoskeletal and dermatology programs.

Financial strength Recent revenue of approximately $21.1M in 2024 and a $10M credit facility indicate solid growth and financing capacity to scale operations, enhance data infrastructure, and support larger translational research collaborations with pharma and biotech customers.

Strategic partnerships Active collaboration with PV Reporter and engagement with 35 of the top global pharma/biotech companies demonstrate a proven track record in patient-driven data and biospecimen capabilities, creating clear entry points for expanded study networks, co-development opportunities, and preferred supplier agreements.

Global recognition Consistent accolades as a Great Place to Work and listings on Inc. 5000 and Best Workplaces in Biopharma enhance recruiting and employer branding, which can be leveraged to attract larger client programs, specialized talent augmentation, and faster onboarding for joint research initiatives.

Data and access leadership Sanguine’s model of direct-to-patient engagement, in-home sample collection, and annotated biospecimens positions it to offer integrated real-world data packages, biomarker validation support, and rapid study execution services to sponsors seeking faster go/no-go decisions and stronger clinical readouts.